Time is running out. No excuses to delay implementation of antimicrobial stewardship programmes: impact, sustainability, resilience and efficiency through an interrupted time series analysis (2017-2022).

Giovanni Del Fabro, Sergio Venturini, Manuela Avolio, Giancarlo Basaglia, Astrid Callegari, Igor Bramuzzo, Barbara Basso, Chiara Zanusso, Anna Rizzo, Giuseppe Tonutti, Michele Chittaro, Eva Fiappo, Maurizio Tonizzo, Massimo Crapis
Author Information
  1. Giovanni Del Fabro: Department of Infectious Diseases, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, via Montereale 24, Pordenone 33170, Italy. ORCID
  2. Sergio Venturini: Department of Infectious Diseases, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, via Montereale 24, Pordenone 33170, Italy.
  3. Manuela Avolio: Department of Microbiology, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  4. Giancarlo Basaglia: Department of Microbiology, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  5. Astrid Callegari: Department of Infectious Diseases, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, via Montereale 24, Pordenone 33170, Italy.
  6. Igor Bramuzzo: Department of Infectious Diseases, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, via Montereale 24, Pordenone 33170, Italy.
  7. Barbara Basso: Hospital Pharmacy, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  8. Chiara Zanusso: Hospital Pharmacy, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  9. Anna Rizzo: Hospital Pharmacy, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  10. Giuseppe Tonutti: Hospital Health Direction, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  11. Michele Chittaro: Hospital Health Direction, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  12. Eva Fiappo: Hospital Health Direction, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  13. Maurizio Tonizzo: Department of Internal Medicine, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, Pordenone, Italy.
  14. Massimo Crapis: Department of Infectious Diseases, ASFO 'Santa Maria degli Angeli' Hospital of Pordenone, via Montereale 24, Pordenone 33170, Italy.

Abstract

Introduction: The WHO declared antimicrobial resistance (AMR) a significant concern in 2014, sparking initiatives to ensure responsible antibiotic use. In human medicine, Antimicrobial Stewardship Programmes (ASPs) in hospitals play a pivotal role in combating AMR. Although evidence supports the effectiveness of ASPs in optimizing antimicrobial use, often the lack of resources becomes an excuse to limit their dissemination and use. This paper provides a comprehensive report on a 6-year analysis of an ASP implemented in a healthcare region in north-east Italy.
Methods: A retrospective data collection was conducted to assess the programme's impact on antibiotic consumption expressed as DDDs/100 patient-days, its sustainability over time, resilience during the COVID-19 pandemic and the efficiency of the ASP (relationship between workload and human resources).
Results: A substantial overall reduction in antibiotic consumption (-14%), particularly in fluoroquinolones (-64%) and carbapenems (-68%), was demonstrated, showcasing the programme's impact. Sustainability was confirmed through enduring trends in antibiotic consumption and ecological analysis over time. The ASP demonstrates resilience by maintaining positive trends even amid the challenging COVID-19 pandemic. Efficiency was underscored by an increase in on-site consultations despite consistent human resources until 2021.
Conclusions: This study offers insights into the prolonged success of a resource-efficient ASP, emphasizing the crucial role of long-term commitment in fostering responsible antibiotic use in the context of global health challenges such as AMR.

References

  1. Clin Infect Dis. 2021 May 18;72(10):e533-e541 [PMID: 32820807]
  2. J Hosp Infect. 2019 Aug;102(4):369-376 [PMID: 30880265]
  3. Clin Microbiol Infect. 2017 Nov;23(11):799-805 [PMID: 28750920]
  4. J Antimicrob Chemother. 2019 Oct 1;74(10):2844-2847 [PMID: 31299072]
  5. Open Forum Infect Dis. 2023 Aug 01;10(9):ofad412 [PMID: 37674632]
  6. Clin Infect Dis. 2017 Aug 15;65(4):697-698 [PMID: 28472293]
  7. Implement Sci. 2017 Sep 2;12(1):110 [PMID: 28865479]
  8. Front Microbiol. 2017 Nov 02;8:2124 [PMID: 29163414]
  9. J Hosp Infect. 2022 Apr;122:72-83 [PMID: 35077810]
  10. Antimicrob Resist Infect Control. 2017 Jan 13;6:11 [PMID: 28101333]
  11. J Antimicrob Chemother. 2007 May;59(5):833-40 [PMID: 17387116]
  12. Int J Environ Res Public Health. 2018 Dec 23;16(1): [PMID: 30583571]
  13. Lancet Infect Dis. 2017 Sep;17(9):990-1001 [PMID: 28629876]
  14. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4840-52 [PMID: 27246783]
  15. Clin Microbiol Infect. 2017 Nov;23(11):819-825 [PMID: 28571767]
  16. Implement Sci. 2013 Jun 20;8:70 [PMID: 23786847]
  17. Clin Microbiol Infect. 2021 Apr;27(4):520-531 [PMID: 33418017]
  18. J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi50-vi58 [PMID: 29878222]
  19. Antibiotics (Basel). 2020 Dec 01;9(12): [PMID: 33271843]
  20. Infect Dis Clin North Am. 2023 Dec;37(4):683-714 [PMID: 37735012]
  21. Expert Rev Anti Infect Ther. 2022 May;20(5):749-772 [PMID: 34895002]
  22. Antibiotics (Basel). 2021 Jan 29;10(2): [PMID: 33573070]
  23. Healthcare (Basel). 2023 Jul 05;11(13): [PMID: 37444780]
  24. Antibiotics (Basel). 2021 Jan 23;10(2): [PMID: 33498716]
  25. BMC Health Serv Res. 2023 May 17;23(1):502 [PMID: 37198604]
  26. Clin Microbiol Infect. 2016 Sep;22(9):812.e9-812.e17 [PMID: 27373529]
  27. Am J Health Syst Pharm. 2017 Nov 1;74(21):1785-1790 [PMID: 28947624]
  28. Med Mal Infect. 2016 Jun;46(4):200-6 [PMID: 27021932]
  29. Clin Infect Dis. 2016 May 15;62(10):e51-77 [PMID: 27080992]
  30. Health Res Policy Syst. 2020 Jun 8;18(1):60 [PMID: 32513200]
  31. Probiotics Antimicrob Proteins. 2023 Aug 16;: [PMID: 37584833]
  32. Antibiotics (Basel). 2022 Jun 20;11(6): [PMID: 35740232]
  33. BMC Health Serv Res. 2023 Jul 19;23(1):770 [PMID: 37468860]
  34. Clin Infect Dis. 2001 Nov 15;33(10):1661-7 [PMID: 11595982]
  35. Clin Infect Dis. 2003 Apr 15;36(8):1013-7 [PMID: 12684914]
  36. Pediatr Infect Dis J. 2022 Mar 1;41(3S):S10-S17 [PMID: 35134035]
  37. J Antimicrob Chemother. 2020 Nov 1;75(11):3386-3390 [PMID: 32766706]
  38. Int J Environ Res Public Health. 2022 Mar 28;19(7): [PMID: 35409687]
  39. Clin Microbiol Infect. 2017 Nov;23(11):785-787 [PMID: 28778544]
  40. Infect Control Hosp Epidemiol. 2020 Jan;41(1):102-112 [PMID: 31727195]
  41. Implement Sci. 2011 Apr 23;6:42 [PMID: 21513547]
  42. Clin Microbiol Infect. 2018 Dec;24(12):1273-1279 [PMID: 30036665]
  43. Infect Control Hosp Epidemiol. 2020 Dec;41(12):1429-1435 [PMID: 33100246]
  44. J Clin Microbiol. 2017 Mar;55(3):715-723 [PMID: 28031432]
  45. Clin Microbiol Infect. 2003 Jul;9(7):724-6 [PMID: 12925117]
  46. Antibiotics (Basel). 2022 May 10;11(5): [PMID: 35625282]
  47. Curr Treat Options Infect Dis. 2014;6(2):101-112 [PMID: 25999798]
  48. Mayo Clin Proc. 2011 Nov;86(11):1113-23 [PMID: 22033257]
  49. Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543 [PMID: 28178770]
  50. Stud Health Technol Inform. 2023 Jun 22;304:62-66 [PMID: 37347570]
  51. Int J Antimicrob Agents. 2015 Mar;45(3):203-12 [PMID: 25630430]
  52. Scand J Infect Dis. 2011 Dec;43(11-12):912-7 [PMID: 21867475]
  53. Antibiotics (Basel). 2021 Dec 11;10(12): [PMID: 34943730]
  54. J Hosp Infect. 2019 Apr;101(4):447-454 [PMID: 30597175]
  55. Antibiotics (Basel). 2022 Sep 16;11(9): [PMID: 36140036]
  56. J Am Coll Clin Pharm. 2022 Jul;5(7):707-715 [PMID: 35572210]
  57. Clin Infect Dis. 2011 Oct;53(7):651-62 [PMID: 21890770]

Word Cloud

Created with Highcharts 10.0.0antibioticuseASPantimicrobialAMRhumanresourcesanalysisimpactconsumptiontimeresilienceresponsibleASPsroleprogramme'ssustainabilityCOVID-19pandemicefficiencytrendsIntroduction:WHOdeclaredresistancesignificantconcern2014sparkinginitiativesensuremedicineAntimicrobialStewardshipProgrammeshospitalsplaypivotalcombatingAlthoughevidencesupportseffectivenessoptimizingoftenlackbecomesexcuselimitdisseminationpaperprovidescomprehensivereport6-yearimplementedhealthcareregionnorth-eastItalyMethods:retrospectivedatacollectionconductedassessexpressedDDDs/100patient-daysrelationshipworkloadResults:substantialoverallreduction-14%particularlyfluoroquinolones-64%carbapenems-68%demonstratedshowcasingSustainabilityconfirmedenduringecologicaldemonstratesmaintainingpositiveevenamidchallengingEfficiencyunderscoredincreaseon-siteconsultationsdespiteconsistent2021Conclusions:studyoffersinsightsprolongedsuccessresource-efficientemphasizingcruciallong-termcommitmentfosteringcontextglobalhealthchallengesTimerunningexcusesdelayimplementationstewardshipprogrammes:interruptedseries2017-2022

Similar Articles

Cited By